Interferon beta produces only small benefits in multiple sclerosisBMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7142.1407g (Published 09 May 1998) Cite this as: BMJ 1998;316:1407
- Louise McKee
Treatment of relapsing remitting multiple sclerosis with interferon beta produces only a small improvement in overall quality of life at considerable cost to the health service, according to a report commissioned by the NHS Executive's health technology assessment programme.
Researchers used existing data from clinical trials of interferon beta, information on the clinical course of multiple sclerosis, and new data on costs and quality of life to construct a model for calculating cost effectiveness. The cost effectiveness over five years was estimated …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial